Evomela melphalan regulatory update

FDA approved an NDA from Spectrum for Evomela melphalan as a high-dose conditioning treatment in patients with multiple myeloma (MM) undergoing autologous stem cell transplantation (ASCT) and for palliative treatment of MM patients for whom oral therapy is not appropriate. The approval triggered a $6 million milestone payment to Ligand under a 2013 deal granting Spectrum exclusive, worldwide rights to develop and commercialize the product (see BioCentury, March 18, 2013). ...